Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

32.91 +0.63 (+1.95%)

Official Closing Price Updated: 7:00 PM EST, Mar 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

32 33 Next >

Forget Teva: This Dividend Top Dog Is the Real Value Buy Today ↗

March 04, 2026

Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead.

Via The Motley Fool

Topics Intellectual Property

Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding ↗

March 04, 2026

Duquesne Family Office's billionaire boss meaningfully pared down two high-flying stocks in the fourth quarter and made a $301 million wager on a popular sector-based exchange-traded fund (ETF).

Via The Motley Fool

Topics Artificial Intelligence ETFs Retirement

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug

March 03, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Shows Perfect Technical Setup for Breakout ↗

January 28, 2026

Via Chartmill

Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive

March 03, 2026

As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent...

Via Finterra

Topics Economy Initial Public Offering Retirement

The Best Healthcare Stock to Invest $1,000 in Right Now ↗

March 02, 2026

There's nothing generic about this drugmaker's recent performance and continued prospects.

Via The Motley Fool

Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole ↗

February 27, 2026

Sorry, Teva, it's not you ... it's me.

Via The Motley Fool

Topics Intellectual Property

The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy

February 26, 2026

As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the...

Via Finterra

Topics Economy

Bridger Dumps 301,000 Bath & Body Works Shares Worth $7.7 Million ↗

February 24, 2026

This specialty retailer delivers personal care and home fragrance products through a broad network of stores and online channels.

Via The Motley Fool

Topics Economy Regulatory Compliance

Teva to Present at the Upcoming Investor Conferences in March

February 24, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Inside a $75 Million Albertsons Stock Sale as Shares Sink 8% in a Year ↗

February 20, 2026

Albertsons operates a nationwide grocery network, pairing in-house food production with a broad mix of retail and pharmacy services.

Via The Motley Fool

Topics Regulatory Compliance

AvePoint Stock Down 47% as One Fund Slashes Stake by $65.9 Million ↗

February 20, 2026

This technology firm offers cloud-based data management and compliance tools for organizations using Microsoft 365 and other platforms.

Via The Motley Fool

Topics Regulatory Compliance

Teva Pharmaceuticals Seeks FDA Greenlight For New Schizophrenia Treatment ↗

February 20, 2026

The application was based on data from a late-stage trial in which TEV-'749 administered as a once-monthly subcutaneous injection demonstrated an efficacy and safety profile consistent with currently...

Via Stocktwits

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

February 20, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

CORT Stock Drops After Appeals Court Sides With Teva In Korlym Patent Fight ↗

February 19, 2026

The ruling pertains to Corcept’s Korlym tablets for the treatment of Cushing syndrome.

Via Stocktwits

Topics Intellectual Property

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

February 17, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse

February 10, 2026

February 10, 2026 Introduction As of February 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a pivotal juncture. Five years after its high-profile inception, the company has shed its skin as a...

Via Finterra

Topics Economy World Trade

Teva (TEVA) Q4 2024 Earnings Call Transcript ↗

February 05, 2026

Teva (TEVA) Q4 2024 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Teva (TEVA) Q3 2024 Earnings Call Transcript ↗

February 05, 2026

Teva (TEVA) Q3 2024 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Harel Insurance Sold $330 Million of Invesco KBW Bank ETF ↗

February 05, 2026

Invesco KBW Bank ETF tracks a benchmark of major U.S. banking institutions, offering targeted sector exposure and a moderate yield.

Via The Motley Fool

Topics ETFs Regulatory Compliance

Aytu BioPharma AYTU Q2 2026 Earnings Transcript ↗

February 03, 2026

Aytu BioPharma AYTU Q2 2026 Earnings Transcript

Via The Motley Fool

Bank ETF Up 20% in a Year, but This Fund Just Cut a $10 Million Position ↗

January 29, 2026

The Invesco KBW Bank ETF tracks a sector-specific index of leading U.S. banking firms, emphasizing large and regional institutions.

Via The Motley Fool

Topics ETFs Regulatory Compliance

Teva (TEVA) Q3 2025 Earnings Call Transcript ↗

January 28, 2026

Teva (TEVA) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology

January 28, 2026

As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused...

Via Finterra

Topics Economy Intellectual Property

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

January 28, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

The $100 Billion Milestone: Johnson & Johnson Pivots from 'Steady' 2025 to Growth-Focused 2026

January 27, 2026

NEW BRUNSWICK, N.J. — Johnson & Johnson (NYSE: JNJ) has officially closed the chapter on a year many analysts described as "transitional," reporting full-year 2025 earnings that met expectations while...

Via MarketMinute

Topics Earnings Economy Government

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

January 27, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion

January 20, 2026

As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results....

Via MarketMinute

Topics Bankruptcy Earnings Economy

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

January 14, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation

January 14, 2026

Date: January 14, 2026 Viatris Inc. (NASDAQ: VTRS) stands at a critical crossroads in early 2026. After years of functioning as a complex, debt-laden conglomerate formed from the massive merger of...

Via Finterra

Topics Earnings Economy Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

32 33 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.